Association between severity of lower urinary tract symptoms, erectile dysfunction and metabolic syndrome

References

• Rosen R, Altwein J, Boyle P, Kirby R S, Lukacs B, Meuleman E, O'Leary M P, Puppo P, Robertson C, Giuliano F. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003; 44: 637–649
   PubMed Web of Science ®Google Scholar
• Vallancien G, Emberton M, Harving N, van Moorselaar R J. Alf-One Study Group. Sexual dysfunction in 1274 European men suffering from lower urinary tract symptoms. J Urol 2003; 169: 2257–2261
   PubMed Web of Science ®Google Scholar
• Li M K, Garcia L A, Rosen R. Lower urinary tract symptoms and male sexual dysfunction in Asia: a survey of aging men from five Asian countries. BJU Int 2005; 96: 1339–1354
   PubMed Web of Science ®Google Scholar
• Aslan G, Cavus E, Karas H, Oner O, Duran F, Esen A. Association between lower urinary tract symptoms and erectile dysfunction. Arch Androl 2006; 52: 155–162
   PubMed Web of Science ®Google Scholar
• Demir O, Murat N, Aslan G, Gidener S, Esen A. Effect of doxazosin with and without rho-kinase inhibitor on human corpus cavernosum smooth muscle in the presence of bladder outlet obstruction. J Urol 2006; 175: 2345–2349
   PubMed Web of Science ®Google Scholar
• Ellenberg M. Development of urinary bladder dysfunction in diabetes mellitus. Ann Int Med 1980; 92: 321–323
   PubMed Web of Science ®Google Scholar
• Rohrmann S, Smit E, Giovanucci E, Platz E A. Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). Int J Obesity 2005; 29: 310–316
   PubMed Web of Science ®Google Scholar
• Ozden C, Ozdal L O, Urgancioglu G, Koyuncu H, Gokkaya S, Memis A. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol 2007; 51: 199–206
   PubMed Web of Science ®Google Scholar
• Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–2497
   PubMed Web of Science ®Google Scholar
• Kasturi S, Russell S, McVary K T. Metabolic syndrome and lower urinary tract symptoms secondary to benign prostatic hyperplasia. Curr Urol Rep 2006; 7: 288–292
   PubMedGoogle Scholar
• Hammarsten J, Högstedt B, Holthuis N, Mellström D. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 1998; 1: 157–162
   PubMed Web of Science ®Google Scholar
• McVary K. Erectile dysfunction and lower urinary tract symptoms secondary to BPH. Eur Urol 2005; 47: 838–845
   PubMed Web of Science ®Google Scholar
• Berger A P, Bartsch G, Deibl M, Alber H, Pachinger O, Fritsche G, Rantner B, Fraedrich G, Pallwein L, Aigner F, Horninger W, Frauscher F. Atherosclerosis as a risk factor for benign prostatic hyperplasia. BJU Int 2006; 98: 1038–1042
   PubMed Web of Science ®Google Scholar
• McVary K T, Rademaker A, Lloyd G L, Gann P. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2005; 174: 1327–1333
   PubMed Web of Science ®Google Scholar
• Kaiser D R, Billups K, Mason C, Wetterling R, Lundberg J L, Bank A J. Impaired brachial artery endothelium-dependent and -independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease. J Am Coll Cardiol 2004; 43: 179–184
   PubMed Web of Science ®Google Scholar
• Hammarsten J, Hogstedt B. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press 1999; 8: 29–36
   PubMed Web of Science ®Google Scholar
• Pradidarcheep W. Lower urinary tract symptoms and its potential relation with late-onset hypogonadism. Aging Male 2008; 11: 51–55
   PubMed Web of Science ®Google Scholar
• Lee E, Park M S, Shin C, Lee H, Yoo K, Kim Y, Shin Y, Paik H Y, Lee C. A high-risk group for prostatism: a population-based epidemiological study in Korea. Br J Urol 1997; 79: 736–741
   PubMedGoogle Scholar
• Joseph M A, Harlow S D, Wei J T, Sarma A V, Dunn R L, Taylor J M, James S A, Cooney K A, Doerr K M, Montie J E, Schottenfeld D. Risk factors for lower urinary tract symptoms in a population-based sample of African-American men. Am J Epidemiol 2003; 157: 906–914
   PubMed Web of Science ®Google Scholar
• Field A E, Colditz G A, Willett W C, Longcope C, McKinlay J B. The relation of smoking, age, relative weight, and dietary intake to serum adrenal steroids, sex hormones, and sex hormone-binding globulin in middle-aged men. J Clin Endocrinol Metab 1994; 79: 1310–1316
   PubMed Web of Science ®Google Scholar
• Haass M, Kubler W. Nicotine and sympathetic neurotransmission. Cardiovasc Drugs Ther 1997; 10: 657–665
   PubMed Web of Science ®Google Scholar
• Rohrmann S, Nelson W G, Rifai N, Kanarek N, Basaria S, Tsilidis K K, Smit E, Giovannucci E, Platz E A. Serum sex steroid hormones and lower urinary tract symptoms in Third National Health and Nutrition Examination Survey (NHANES III). Urology 2007; 69: 708–713
   PubMed Web of Science ®Google Scholar
• Miwa Y, Kaneda T, Yokoyama O. Association between lower urinary tract symptoms and serum levels of sex hormones in men. Urology 2008; 72: 552–555
   PubMed Web of Science ®Google Scholar
• Koritsiadis G, Stravodimos K, Mitropoulos D, Doumanis G, Fokitis I, Koritsiadis S, Constantinides C. Androgens and bladder outlet obstruction: a correlation with pressure-flow variables in a preliminary study. BJU Int 2008; 101: 1542–1546
   PubMed Web of Science ®Google Scholar
• Laaksonen D E, Niskanen L, Punnonen K, Nyyssönen K, Tuomainen T P, Valkonen V P, Salonen R, Salonen J T. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004; 27: 1036–1041
   PubMed Web of Science ®Google Scholar
• Wang C, Swerdloff R S, Iranmanesh A, Dobs A, Snyder P J, Cunningham G, Matsumoto A M, Weber T, Berman N, Testosterone Gel Study Group. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 2000; 85: 2839–2853
   PubMed Web of Science ®Google Scholar
• Bhasin S, Bagatell C J, Bremner W J, Plymate S R, Tenover J L, Korenman S G, Nieschlag E. Issues in testosterone replacement in older men. J Clin Endocrinol Metab 1998; 83: 3435–3448
   PubMed Web of Science ®Google Scholar
• Holmäng A, Björntorp P. The effects of testosterone on insulin sensitivity in male rats. Acta Physiol Scand 1992; 146: 505–510
   PubMedGoogle Scholar
• Traish A M, Toselli P, Jeong S J, Kim N N. Adipocyte accumulation in penile corpus cavernosum of the orchiectomized rabbit: a potential mechanism for veno-occlusive dysfunction in androgen deficiency. J Androl 2005; 26: 242–248
   PubMed Web of Science ®Google Scholar
• Makhsida N, Shah J, Yan G, Fisch H, Shabsigh R. Hypogonadism and metabolic syndrome: implications for testosterone therapy. J Urol 2005; 174: 827–834
   PubMed Web of Science ®Google Scholar